CMC, AI, and biotech news, updated daily
News from major industry publications, the FDA, and the EMA, in plain words. Each story tells you what it means for a drug program. The list updates each day.
Updated 6 Oct 2026 · 61 stories from 12 publications · How to read biotech and CMC news
Yesterday
- Facktor Ventures started an early-stage venture fund for safety-net healthcare. The organizations that deliver care become majority owners of the fund as limited partners.
- A study in human microglia and brain tissue suggests that an existing drug candidate that targets P2X7R can treat inflammatory brain conditions, such as TBI.
What it means: This is early research. Most early drug candidates do not reach approval, so read this news as a first step. How to read this type of news →
- Richard Bonneau, the global head of AI for drug discovery at Genentech, left the company effective immediately. Genentech is a unit of Roche.
What it means: A new leader can change the priorities of a company. A leadership change does not change approved processes or commitments by itself. How to read this type of news →
- New regulations from the Trump administration would make health care pricing disclosures clearer. The administration continues its effort to show the cost of health care.
What it means: Guidance shows how a regulator expects companies to do the work. A draft can change before it is final, so teams compare it with their current plans. How to read this type of news →
- The FDA extended its review of denecimig, a hemophilia A injection from Novo. The agency said ongoing facility remediation activities, seen during a pre-license inspection, caused the delay.
What it means: A pre-license inspection finding can delay a review even when the clinical data is complete. Facility remediation at each manufacturing site is part of the filing plan. How to read this type of news →
- Utah plans to let an AI product evaluate patients and write new drug prescriptions without prior human review. The state also has more health AI pilots for women's health.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
- Shionogi paid $2B for IntraBio, a rare disease startup in Texas. The deal gives Shionogi a marketed treatment for two inherited conditions.
What it means: A marketed treatment comes with an approved process and an active supply chain. The buyer must keep supply steady while it takes over manufacturing and quality. How to read this type of news →
- Vaxcyte said its experimental pneumococcal vaccine VAX-31 met its key endpoints in a Phase 3 trial with adults. Shares of Vaxcyte jumped 35% on Monday morning.
What it means: When a vaccine meets its endpoints in a pivotal trial, the focus moves to commercial supply. The process must reach validated scale before the company can file. How to read this type of news →
- Scientists won the Nobel Prize for optogenetics, the approach behind light-activated gene therapy. Pharma companies now study its use to treat ophthalmic conditions.
- Genmab said its ovarian cancer drug Rina-S got a 45.9% objective response rate in patients with platinum-resistant ovarian cancer. Jaypirca from Lilly got a label expansion.
What it means: An ADC joins an antibody to a drug payload, so the CMC plan controls more than one supply chain. The Jaypirca label expansion adds demand on the approved process. How to read this type of news →
- An article examines whether continuous tableting can end scale-up for complex oral drugs.
- Roche will pay Alector $100 million upfront in a neuroscience deal. Parkinson's disease is a focus of the deal, which follows the collapse of a separate Alector partnership.
What it means: A deal gives one company rights to the drug of another company. The buyer pays the upfront amount now, and milestone payments only if the program reaches set goals. How to read this type of news →
- The FDA asked the public for input on approaches it considers for the design of early-phase clinical trials of ibogaine drug products.
What it means: This RFI gives developers of ibogaine drug products a chance to comment before the agency sets its approach to early-phase trial design. How to read this type of news →
- An article lists the biggest biotech funding rounds in September 2026. It also names Moderna, Amylyx Pharmaceuticals, and Braveheart Bio, which got the biggest rounds in August 2026.
- Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial. The result lets Vaxcyte compete with Pfizer and Merck.
- An article examines whether vaccines can one day prevent every cancer. It reviews which cancers vaccines can beat and which need more creative approaches.
- Sensible Biotechnologies raised $47 million in a Series A round to develop its manufacturing approach for mRNA therapeutics.
What it means: A new mRNA manufacturing approach must show consistent product quality before programs adopt it. A program that changes its platform needs comparability data for the change. How to read this type of news →
- An article examines how AI changes biopharma manufacturing facilities. It says AI helps researchers find promising drug candidates in months instead of years.
What it means: AI in a manufacturing facility needs the same validation and change control as other plant systems. Faster discovery does not remove the need for a qualified process. How to read this type of news →
- A melanoma vaccine succeeded in a late-stage clinical trial. An article examines whether other cancer vaccines will work and whether mRNA can do the task.
What it means: A trial result shows if a medicine works and is safe at that stage. A good Phase 3 result usually starts the work to file, including process validation. How to read this type of news →
- An article describes a platform that delivers oral peptides and small molecules through the gut wall.
What it means: For oral peptides, the delivery platform is part of how the drug works. The CMC package then puts more weight on formulation and process controls. How to read this type of news →
4 Oct 2026
- At a privacy symposium, experts discussed how AI helps healthcare organizations monitor data and investigate data breaches. They also named the privacy risks that these organizations must monitor.
What it means: A trial result shows if a medicine works and is safe at that stage. A good Phase 3 result usually starts the work to file, including process validation. How to read this type of news →
2 Oct 2026
- In Debunked Episode 30, Arundhati Parmar and Samir Batra discussed how the CMS ACCESS Model can advance value-based care goals. The episode also covers AI and UnitedHealth.
What it means: A trial result shows if a medicine works and is safe at that stage. A good Phase 3 result usually starts the work to file, including process validation. How to read this type of news →
- Bayer described plans for a $2.2 billion manufacturing site in New Albany, Ohio. The site would create about 600 new jobs in the area.
What it means: A site that adds about 600 jobs must hire and train staff before it makes commercial product. In site readiness, trained people count as much as qualified equipment. How to read this type of news →
- FDA Chief Scientist Steven Kozlowski said the updated FARS will highlight aging and longevity medicine. He said the update would come out early in FY 2027 but gave no further timing.
- The FDA opened a new clinical trial modernization office within the Center for Drug Evaluation and Research. The agency said its focus on faster clinical trials led to the new office.
What it means: When trials start faster, CMC teams must have investigational product ready earlier. Clinical supply plans must keep pace with the new trial timelines. How to read this type of news →
- An episode of the AI Pulse Check series covers shadow AI, trade secrets, and the API race.
What it means: Shadow AI means staff use AI tools outside approved systems. In regulated work, this puts trade secrets and data integrity at risk. How to read this type of news →
- Litfulo, a daily pill from Pfizer, improved skin pigment measures in two pivotal studies in vitiligo, which supports submissions to the FDA and EMA. An Incyte topical cream is currently the only FDA-approved therapy for this skin disorder.
What it means: Pivotal data that support FDA and EMA submissions start the CMC work for both agencies. The CMC sections must meet the requirements of each region. How to read this type of news →
- This article gives a summary of regulatory news from September 2026.
- The EMA safety committee, PRAC, held its monthly meeting from 28 September to 1 October. It assessed the safety of medicines.
- Novartis made a $7.8bn deal with Abogen for autoimmune BiTEs. ABO2203 from Abogen uses an mRNA-encoded system to make a T-cell engager protein in vivo.
What it means: Here the product is an mRNA system, and the patient makes the protein in vivo. The CMC work controls the mRNA product, not a purified protein. How to read this type of news →
- An interview examines how Valo, a company from Flagship, uses human data in AI drug discovery. The guest says AI alone was never going to be the answer.
What it means: A trial result shows if a medicine works and is safe at that stage. A good Phase 3 result usually starts the work to file, including process validation. How to read this type of news →
- An article describes VIPerturb-seq, a method for genome-wide CRISPR screens at single-cell resolution.
1 Oct 2026
- The FDA approved the Autus Size-Adjustable Valve, the first heart valve designed to grow with children. Surgeons implant it in pediatric patients with congenital pulmonary valve disease.
What it means: An approval lets the company sell the medicine for this use in that market. The approved process and its controls then become fixed commitments. How to read this type of news →
- Lilly ended its partnership with Foghorn after a cancer drug disappointed in testing. Teva and Samsung Bioepis expanded a partnership, and Varda brought in $251 million.
What it means: An approval lets the company sell the medicine for this use in that market. The approved process and its controls then become fixed commitments. How to read this type of news →
- United Therapeutics won a legal victory, and Camzyos from Bristol Myers Squibb got approval for kids. Shares of Nektar Therapeutics dropped 20% after the biotech shared long-term data.
What it means: An approval lets the company sell the medicine for this use in that market. The approved process and its controls then become fixed commitments. How to read this type of news →
- An article examines whether AI increases healthcare costs instead of cutting them. It cites an analysis by the Blue Cross Blue Shield Association.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
- EMA gave advice on end-of-year submission dates for type I variations in 2026. The advice is for marketing authorisation holders who want an outcome in 2026.
- This AI Deep Dive article by Drapeau discusses a control lab and testing for flavor.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
- In an interview, the CEO of USP asks manufacturers to act now to stop drug shortages.
What it means: Shortage prevention starts in manufacturing. A second qualified source and stable quality systems reduce the risk of a supply gap. How to read this type of news →
- The Executive Director of EMA gave a speech at a women's health workshop in Amsterdam on 28 September 2026.
- An article describes how ligation can help scale up siRNA manufacturing.
30 Sep 2026
- Health tech companies made several major funding announcements in September. An article lists 4 of the biggest funding rounds.
- An ICU physician and startup CMO argues that the bigger AI danger in healthcare is not autonomy. The danger is that organizations use AI mainly for efficiency and leave providers with more complexity and regulation.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
- An article examines how AI can help people and organizations in social care. It says AI can help them move faster, see patterns earlier, and coordinate better, but not replace people.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
- The FDA started a nationwide effort to recruit more qualified people for its advisory committees. These independent bodies inform important public health decisions in America.
What it means: A new or larger plant adds supply capacity. A new site must pass qualification and process validation before it can make commercial product. How to read this type of news →
29 Sep 2026
- Federal prosecutors charged Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, in a transnational counterfeit drug distribution scheme. An FDA investigation led to the charges.
- An episode of the AI Pulse Check series covers INTerpath-001, precision ML, and governance gaps in pharma.
What it means: AI governance in pharma needs a named owner, a validation record, and a human review step for each use. Gaps in these records become audit findings. How to read this type of news →
- An article explains how to build a CMC playbook for BsAb, with decision frameworks, risks, and readiness.
- This eBook from September 2026 covers advances in formulation.
- Peak XV raised the investment ceiling for Surge seed rounds to $5M and named 18 startups in its new cohort. Thirteen of the 18 target global markets, and more than half are in India.
What it means: A funding round gives a company money to run its programs. A larger round often pays for clinical trials and the first manufacturing work. How to read this type of news →
28 Sep 2026
- The FDA approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis. It is the first treatment for MCT8 deficiency.
What it means: A tablet for oral suspension must disperse before the patient takes it. The product quality controls must then include how the tablet disperses. How to read this type of news →
- The FDA plans to evaluate changes to the PMTA regulatory framework. The agency reviews its experience with the PMTA rule and a federal lawsuit in Texas that challenges the framework.
What it means: Guidance shows how a regulator expects companies to do the work. A draft can change before it is final, so teams compare it with their current plans. How to read this type of news →
- An article explains what the NAM rule from the FDA means for CMC teams.
What it means: Guidance shows how a regulator expects companies to do the work. A draft can change before it is final, so teams compare it with their current plans. How to read this type of news →
- This is part 3 of a series on CMC strategies from AAPS PharmSci 360.
- An article examines how a $2.13B deal for a KRAS G12D inhibitor tests cross-border tech transfer.
What it means: A cross-border deal moves the process between companies and between regulators. The tech transfer plan must cover analytical methods, supply, and the filing in each region. How to read this type of news →
26 Sep 2026
- Blue Cross Blue Shield says hospital use of AI tools added $942 million in healthcare spending over a two-year period.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
25 Sep 2026
- Part 2 of this article gives practical considerations for CGMP documentation systems. It covers risk-based life cycle management of master production and control records for data integrity and GMP inspection readiness.
What it means: Master production and control records define how each batch gets made, so one error repeats in every batch. Risk-based control of these records supports inspection readiness. How to read this type of news →
24 Sep 2026
- An article examines Efsitora, a weekly basal insulin, and calls it a new CMC benchmark for biologics.
- An article discusses a report in which Anthropic says it blocked efforts to use its Claude AI systems for undesirable functions. These functions include possible design of bioweapons.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
23 Sep 2026
- A federal court order stops Gold Star Distribution, Inc. from distributing FDA-regulated products until it meets federal legal requirements. The order followed an FDA investigation and persistent insanitary warehouse conditions.
- Enveda raised $311M to bring more nature-derived AI drugs into clinical trials, and the round valued it at $2 billion. Its drugs in testing treat skin conditions and preserve weight loss after people stop GLP-1s.
What it means: This shows where companies or regulators use AI. In GMP work, a named person must still make each quality decision. How to read this type of news →
Each headline links to its publisher. This page shows only headlines, publishers, and dates. The articles belong to their publishers.